Joel Scherer
Managing Director
Jeffrey W. Miller
Sr. Medical Director and Chief Medical Officer
Paul K. Owens
Sr. Director, CMC
Shirley L. Paddock
Sr. Director, Operations and Chief Operating Officer
Ken Olovich
Chief Financial and Procurement Officer
Bill Gaskins
Director, Quality
Dr. Joel Scherer is the Managing Director of Chorus, responsible for overseeing the group in addition to serving as the Medical Director. He brings over 20 years of medical and research experience.
Dr. Scherer, obtained his MD degree from Stanford University in 1981. He holds a BS in chemistry from the University of Wisconsin and a master’s degree in organic chemistry from Harvard University. He completed his medical training in general internal medicine and subspecialty training in cardiology at the University of Rochester/Strong Memorial Hospital from 1981-1987 and practiced invasive cardiology in southern California before joining Lilly. He is a member of the American Heart Association and a Fellow of the American College of Cardiology.
Dr. Scherer joined Eli Lilly and Company in 1994 and has directed the development of multiple compounds from Phase I-IV. He was named Managing Director of the Chorus group in May, 2008. Prior to this, he served as Transition Team Leader and Cardiovascular Medical Director. From 2001-2003 he served as Director, LRL Strategy, where he worked on a number of initiatives including advancing Lilly’s strategy in tailored therapeutics as well as developing alternative R&D business and finance models. His interest in applying alternative development models to address industry productivity challenges was borne out of experiences in co-leading joint teams with strategic Biotech partners where assets were advance on an outsourced model managed on their streamlined operational platforms.
Dr. Scherer, obtained his MD degree from Stanford University in 1981. He holds a BS in chemistry from the University of Wisconsin and a master’s degree in organic chemistry from Harvard University. He completed his medical training in general internal medicine and subspecialty training in cardiology at the University of Rochester/Strong Memorial Hospital from 1981-1987 and practiced invasive cardiology in southern California before joining Lilly. He is a member of the American Heart Association and a Fellow of the American College of Cardiology.
Dr. Scherer joined Eli Lilly and Company in 1994 and has directed the development of multiple compounds from Phase I-IV. He was named Managing Director of the Chorus group in May, 2008. Prior to this, he served as Transition Team Leader and Cardiovascular Medical Director. From 2001-2003 he served as Director, LRL Strategy, where he worked on a number of initiatives including advancing Lilly’s strategy in tailored therapeutics as well as developing alternative R&D business and finance models. His interest in applying alternative development models to address industry productivity challenges was borne out of experiences in co-leading joint teams with strategic Biotech partners where assets were advance on an outsourced model managed on their streamlined operational platforms.
Dr. Jeffrey Miller is a Senior Medical Director and Chief Medical Officer for Chorus responsible for Clinical Pharmacology and Exploratory Medicine.
Dr. Miller joined Lilly in 1995 after completing Fellowships in Endocrinology and Clinical Pharmacology at Stanford University from 1991-95. Dr. Miller has conducted Phase 1 clinical research in the areas of osteoporosis, gynecological disorders, diabetes and obesity. He has served as chairman of the US Exploratory and Biopharm PRCs and Musculoskeletal QP Pod, and served as a standing member of the Musculoskeletal Enduring Team.
He was an Internal Medicine resident at the Strong Memorial Hospital, Rochester, NY, and earned his M.D. at SUNY Syracuse after attending Amherst College.
Dr. Miller joined Lilly in 1995 after completing Fellowships in Endocrinology and Clinical Pharmacology at Stanford University from 1991-95. Dr. Miller has conducted Phase 1 clinical research in the areas of osteoporosis, gynecological disorders, diabetes and obesity. He has served as chairman of the US Exploratory and Biopharm PRCs and Musculoskeletal QP Pod, and served as a standing member of the Musculoskeletal Enduring Team.
He was an Internal Medicine resident at the Strong Memorial Hospital, Rochester, NY, and earned his M.D. at SUNY Syracuse after attending Amherst College.
Dr. Paul Owens is Senior Director of CMC for Chorus. He brings over 11 years of pharmaceutical research experience, joining Eli Lilly and Company in 2003. Dr. Owens is responsible for all aspects of chemistry manufacturing and control (CMC) for the group.
In his previous role at Lilly, Dr. Owens was a Principal Research Scientist at the Tippecanoe Laboratories manufacturing facilities. There he predominantly focused on analytical development for late-phase drug substance projects. Prior to joining Lilly, Dr. Owens worked in analytical development at Pfizer Central Research in Sandwich, UK and worked at AstraZeneca R&D Mölndal, Sweden where he was an Associate Principal Scientist.
A native of Ireland, he received his B.Sc. degree in Analytical Chemistry from Staffordshire University, UK and his PhD degree from the School of Pharmacy at Bradford University, United Kingdom in Pharmaceutical Analysis.
In his previous role at Lilly, Dr. Owens was a Principal Research Scientist at the Tippecanoe Laboratories manufacturing facilities. There he predominantly focused on analytical development for late-phase drug substance projects. Prior to joining Lilly, Dr. Owens worked in analytical development at Pfizer Central Research in Sandwich, UK and worked at AstraZeneca R&D Mölndal, Sweden where he was an Associate Principal Scientist.
A native of Ireland, he received his B.Sc. degree in Analytical Chemistry from Staffordshire University, UK and his PhD degree from the School of Pharmacy at Bradford University, United Kingdom in Pharmaceutical Analysis.
Shirley Paddock is the Senior Director of Operations/Chief Operating Officer for Chorus. She brings over 20 years extensive pharmaceutical research and management experience to her role. Shirley joined Chorus in 2010 and is responsible for the operations and portfolio management for the group.
In her previous role at Lilly, Shirley was a Senior Director of Pharmaceutical Project Management. She has held several positions in clinical development and operations, strategy, and portfolio and project management.
Shirley received her Bachelor of Science in Pharmacy from Purdue University in 1990 and launched her career at Eli Lilly and Company in the field of clinical research. She is a licensed pharmacist. In 2004, Shirley received her Masters of Business Administration from Northwestern Kellogg School of Management.
In her previous role at Lilly, Shirley was a Senior Director of Pharmaceutical Project Management. She has held several positions in clinical development and operations, strategy, and portfolio and project management.
Shirley received her Bachelor of Science in Pharmacy from Purdue University in 1990 and launched her career at Eli Lilly and Company in the field of clinical research. She is a licensed pharmacist. In 2004, Shirley received her Masters of Business Administration from Northwestern Kellogg School of Management.
Mr. Ken Olovich is the Chief Financial and Procurement Officer for Chorus. Ken has over 20 years of pharmaceutical research experience. As one of the original founding members of The Chorus Group in 2002, Ken can be credited with designing and implementing much of the Chorus approach to clinical vendor relations, contracting, finance and budgeting, quality, and general operations.
Prior to Chorus, Mr. Olovich served as Team Leader for Clinical Trial Operations in the Neuroscience Therapeutic Area where he supervised clinical associates and support staff in the planning and implementation of phase I/II neurology and psychiatry clinical trials. Prior to that role, Mr. Olovich was the Clinical Sourcing Team Leader within the Lilly Procurement division.
Ken earned his Masters of Business Administration from Indiana Wesleyan University and his Bachelor of Pharmacy from Purdue University.
Prior to Chorus, Mr. Olovich served as Team Leader for Clinical Trial Operations in the Neuroscience Therapeutic Area where he supervised clinical associates and support staff in the planning and implementation of phase I/II neurology and psychiatry clinical trials. Prior to that role, Mr. Olovich was the Clinical Sourcing Team Leader within the Lilly Procurement division.
Ken earned his Masters of Business Administration from Indiana Wesleyan University and his Bachelor of Pharmacy from Purdue University.
Mr. Bill Gaskins is the Quality Director for Chorus. He brings over 29 years of pharmaceutical experience to Chorus. As Quality Director, Mr. Gaskins is responsible for the quality strategy and oversight for all Chorus GMP, GLP and GCP internal and external activities.
Joining Lilly in 1981, Mr. Gaskins began as an Analytical Chemist and has since held several positions in Quality Assurance, Development, Analytical, and Manufacturing. Mr. Gaskins joined Chorus in 2005 and was instrumental in developing the Chorus CMC strategy and quality oversight processes.
Bill studied Chemistry and Mathematics at Indiana University. He has extensive experience managing CMC contractor organizations in the U.S., Europe, and Asia.
Joining Lilly in 1981, Mr. Gaskins began as an Analytical Chemist and has since held several positions in Quality Assurance, Development, Analytical, and Manufacturing. Mr. Gaskins joined Chorus in 2005 and was instrumental in developing the Chorus CMC strategy and quality oversight processes.
Bill studied Chemistry and Mathematics at Indiana University. He has extensive experience managing CMC contractor organizations in the U.S., Europe, and Asia.